FDA Accepts sBLA for Evkeeza for Children with Rare High Cholesterol.

The article reports on the acceptance for priority review by the U.S. Food and Drug Administration (FDA) of the supplemental biologics license application (sBLA) of Regeneron Pharmaceuticals for its Evkeeza (evinacumab-dgnb) drug for the treatment of children with homozygous familial hypercholesterolemia (HoFH). Also cited is the risk of premature atherosclerotic disease and cardiac events in patients with the condition.